Pre-referral intranasal artesunate powder for cerebral malaria: a proof-of-concept study

Yobouet Ines Kouakou1,2, Aurelien Millet3, Elodie Fromentin4, Nathalie Hauchard5, Gonçalo Farias5, Maxime Fieux6, Aurelie Coudert7, Roukayatou Omorou1, Ibrahim Bin Sa'id1, Adeline Lavoignat1, Guillaume Bonnot1, Anne-Lise Bienvenu1,8† and Stephane Picot1,2*†

Abstract

Background: Malaria still kills young children in rural endemic areas because early treatment is not available. Thus, the World Health Organization recommends the administration of artesunate suppositories as pre-referral treatment before transportation to the hospital in case of severe symptoms with an unavailable parenteral and oral treatment. However, negative cultural perception of the rectal route, and limited access to artesunate suppositories, could limit the use of artesunate suppositories. There is, therefore, a need for an alternative route for malaria pre-referral treatment. The aim of this study was to assess the potential of intranasal route for malaria pre-referral treatment.

Methods: The permeability of artesunate through human nasal mucosa was tested in vitro. The Transepithelial Electrical Resistance (TEER) of the nasal mucosa was followed during the permeation tests. Beside, regional deposition of artesunate powder was assessed with an unidose drug delivery device in each nostril of a nasal cast. Artesunate quantification was performed using Liquid Chromatography coupled to tandem Mass Spectrometry.

Results: The experimental model of human nasal mucosa was successfully implemented. Using this model, artesunate powder showed a much better passage rate through human nasal mucosa than solution (26.8 ± 6.6% versus 2.1 ± 0.3%). More than half (62.3%) of the artesunate dose sprayed in the nostrils of the nasal cast was recovered in the olfactory areas (44.7 ± 8.6%) and turbinates (17.6 ± 3.3%) allowing nose-to-brain and systemic drug diffusion, respectively.

Conclusion: Artesunate powder showed a good permeation efficiency on human nasal mucosa. Moreover it can be efficiently sprayed in the nostrils using unidose device to reach the olfactory area leading to a fast nose-to-brain delivery as well as a systemic effect. Taken together, those results are part of the proof-of-concept for the use of intranasal artesunate as a malaria pre-referral treatment.

Keywords: Severe malaria, Artesunate, Pre-referral treatment, Nose-to-brain delivery, Nasal mucosa, Nasal cast

Background

Malaria is one of the deadliest human infectious diseases, responsible for more than 600,000 deaths in 2021, most of them being young children in sub-Saharan Africa [1, 2]. Whereas a great majority of cases are uncomplicated and successfully treated with oral anti-malarials, severe malaria may occur in non-immune patients, including children under five years old living in high transmission endemic regions [1, 3–5]. A rapid and optimal
anti-malarial treatment is critical to improve the outcome of severe cases. The first-line treatment recommended for severe malaria is intravenous artesunate, a semisynthetic derivative of artemisinin. In rural areas where intravenous treatments are not available, the World Health Organization (WHO) recommends the use of a pre-referral artesunate treatment before addressing the patient to the nearest hospital for appropriate care [1, 6]. Pre-referral artesunate treatment is a single dose of artesunate administered intrarectally to young children (<6 years old) at risk of severe malaria when oral route is unavailable [1, 6]. This pre-referral artesunate treatment using suppositories was demonstrated to reduce the risk of death or permanent disability [6]. Pharmacokinetic studies showed large interindividual variability with a bioavailability of 11.7 to 54.4% (mean = 25.6%), but a 12-h parasite reduction ratio comparable to intravenous artesunate [7]. Among its advantages, the rectal route is non-invasive, usable in unconscious or vomiting patients, allows systemic drug absorption, and avoids at least partially the hepatic first-pass effect [8].

However, a negative cultural perception of the rectal route, as well as reports of melting artesunate suppositories under tropical and subtropical temperatures, and the possible expulsion of the suppositories could limit its use [8–10]. Although two artesunate suppositories have now been prequalified by the WHO, there is still little evidence for the implementation of this pre-referral treatment into endemic countries’ guidelines for severe malaria management [11, 12]. Consequently, the availability of rectal AS is reduced as observed in Ethiopia [13] and Kenya according to a recent national survey of primary public health facilities conducted between 2017 and 2021 [14]. In this context, there is a need for the development of an alternative artesunate pre-referral treatment.

The nasal route was described as an alternative to parenteral and oral routes [15]. It is better accepted than the rectal route and it avoids the first-pass hepatic metabolism. It allows to bypass the blood-brain barrier (BBB) and facilitates the diffusion of drugs directly inside the brain microvasculature constituted by endothelial cells held together by tight junctions leading to continuous and non-fenestrated vessels. This BBB restricts considerably the diffusion of molecules between blood and central nervous system (CNS) [16]. However, rapid alteration of the BBB is associated with a broad spectrum of diseases including cerebral malaria (CM). During CM, the neurovascular unit (NVU), defined as the interaction between of the microvasculature (endothelial and pericyte cells) and neural cells (neurons, astrocyte, microglia) is severely impacted by the local sequestration of infected red blood cells, leading to a neuroinflammatory process and BBB breakdown [17]. This process resulting in neurotoxicity and axonal injury associated with a compromised blood-nerve barrier [18, 19] and perivascular micro-haemorrhages may enable substance to cross the BBB by passive diffusion in both directions [20]. Taken together, these pathological events argued for the potential benefit of artesunate immediate access to the NVU during CM, providing a rapid reduction of the parasite burden and the resultant local inflammatory process. Indeed, the advantages of the nasal route include non-invasiveness, ease of drug administration, and fast drug absorption [15, 21]. The richly vascularized nasal mucosa is effective for drug absorption depending on the regional nasal deposition pattern [22]. The respiratory and the olfactory mucosa are of particular interest for drug absorption: the respiratory mucosa is the preferential site for systemic drug absorption [21, 23, 24], whereas the olfactory mucosa is the preferential site for nose-to-brain drug absorption [21, 24]. The olfactory zone provides a direct access to the brain through the olfactory and trigeminal nerve termination in the cavity. Nose-to-brain drug delivery use the endoneurial microvessels within the nerve fascicle and the perineurium [25, 26] to allow the passage of substances into the brain within minutes. Thus, nasal route allows to bypass the BBB that is of utmost importance in the case of cerebral malaria characterized by sequestration of infected red-blood cells in cerebral capillaries.

Among nasal route shortcomings, are the short retention time of drugs because of mucociliary clearance, metabolic degradation in the nasal cavity, and restricted dosing volume, mostly in children [21, 27, 28]. Over the last two decades, the nasal route was actively assessed for the delivery of various drugs, including vaccines, hormones (insulin, melatonin), opioids, and triptans [15, 29–32]. Nasal administration of sumatriptan powder is now recommended by the Food and Drug Administration (FDA) for the treatment of acute migraines in adults [33]. Compared to the oral route, the nasal route is associated with faster and greater relief of migraines symptoms [34]. Intranasal administration of artesunate for severe malaria treatment would allow both the systemic effects of artesunate, and the nose-to-brain delivery of the drug that would prevent cerebral malaria. This statement is based on preliminary data obtained in a murine model of cerebral malaria that demonstrated the nasal route to prevent the development of complications including cerebral malaria [9]. It was demonstrated that dihydroartemisinin, the main metabolite of artesunate, was recovered into the brain of mice after artesunate intranasal treatment and that early artesunate treatment using intranasal route prevented the development of cerebral malaria.
In this context, there is evidence to further assess the nasal route for artesunate. The objectives of this study were, firstly, to assess artesunate permeation and cytotoxicity using a model of human nasal mucosa and, secondly, to study the nasal deposition pattern of the drug sprayed in a human nasal cast model. This would contribute to the establishment of the nasal route as an alternative for pre-referral treatment of malaria.

Methods

**Chemicals, culture media, and drug solutions**

Artesunate (Chemical Abstract Service CAS number: 88495-63-0; IPCA #19003A6RIII [1kg]) was purchased from IPCA Laboratories Limited (Mumbai, India) through Hepartex (Saint-Cloud, France). Krebs-ringer buffer (KRB) was prepared by dissolving 6.8 g NaCl, 0.4 g KCl, 0.14 g NaH2PO4·H2O, 2.1 g NaHCO3, 3.575 g HEPES, 1.0 g D-glucose, 0.2 g MgSO4·7H2O, and 0.26 g CaCl2·2H2O in 1 L of distilled sterile water. HEPES, D-glucose, and NaHCO3, were purchased from Carl Roth GmbH (Karlsruhe, Germany). All other KRB reagents, 0.25% (w/v) trypsin-EDTA, Trypan blue stain (0.4%), phosphate buffer solution (PBS) tablets, fluorescein sodium salt (NaF), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and Dimethyl sulfoxide (DMSO), were purchased from Sigma-Aldrich Merck (Saint-Louis, Missouri, USA). Culture medium included minimum essential medium (MEM), 10% (v/v) heat-inactivated sterile foetal bovine serum (FBS), 1% (w/v) L-Glutamine, essential medium (MEM), 10% (v/v) heat-inactivated FBS, L-glutamine, and NEAA, were purchased from Sigma-Aldrich Merck (Saint-Louis, Missouri, USA). Culture medium included minimum essential medium (MEM), 10% (v/v) heat-inactivated sterile foetal bovine serum (FBS), 1% (w/v) L-Glutamine, 1% (v/v) non-essential amino-acids (NEAA), and 20µg/ml gentamicin. MEM, heat-inactivated FBS, L-glutamine, and NEAA, were purchased from Sigma-Aldrich Merck (Saint-Louis, Missouri, USA). Nasal epithelial cells RPMI 2650 (RMPI 2650 ECACC 88,031,602) were purchased from the European Collection of Authenticated Cell Cultures (ECACC, Porton, Wiltshire, England). Falcon® Cell-culture flasks, Flacon® 96-well plates and Corning Costar® 12-well plates were purchased from Corning (Glendale, Arizona, USA). ThinCert® tissue-culture inserts for 7-Well plates (polyethylene terephthalate membrane, 1.13 cm², 0.4 mm pore size) were purchased from Greiner Bio-One (Kremsmünster, Austria). Artesunate and artesunate-d4 standards for mass spectrometry (MS) analysis were purchased from Alsachim (Ikkirch-Graffenstaden, France). Ultrapure water was obtained from Biosolve (Dieuze, France) and Thermo Fischer Scientific (Massachusetts, USA). Mass spectrometry-grade (MS-grade) acetonitrile was obtained from Biosolve (Dieuze, France). MS-grade ammonium acetate, acetic acid and methanol were obtained from (Thermo Fischer Scientific (Massachusetts, USA)). Formic acid and ammonium formiate were purchased from Sigma Aldrich (Saint-Louis, Missouri, USA).

MTT stock solution was prepared in PBS at a final concentration of 5 mg/ml. Artesunate stock solutions (30mg/ml) for permeation and MTT tests were prepared into a 5% (w/v) NaHCO3 aqueous solution followed by dilutions into adequate media. Artesunate for MTT assays was diluted into culture medium to final concentrations of 16, 12, 6, 3, 1.5, and 0.75µg/ml. The donor for artesunate permeation studies was either a 0.75µg/ml artesunate solution or a 20µg/mg powder mixture of artesunate and corn-starch. Corn-starch is an inert excipient that was used to dilute the artesunate content in the powder formulation, increase the weight of the formulation, and thus allow its reproducible weighing for the permeation study [35, 36]. The donor solution for NaF permeation tests was prepared by dissolving NaF into KRB (25µg/ml). All molecules’ solutions were filtered before use (0.22µm filter).

**Artesunate formulations**

Artesunate powder and solution formulations were prepared for the permeation studies. For the powder formulation, pure artesunate powder and corn-starch were successively weighted in a plastic flask to a final concentration of 20µg/mg artesunate in corn starch. The powder mixture was homogenized by shaking and the flask was stored at room temperature and protected from light until use. For the solution formulation, 30mg of pure artesunate powder was weighted in a tinted glass vial and dissolved into 1ml of 5% NaHCO3 (W/V) aqueous solution. The resulting solution was diluted in 2ml of NaCl 0.9% (V/V) and then further diluted in KRB to a final artesunate concentration of 0.75µg/ml. The solution formulation was prepared extemporaneously immediately before use.

**Cell culture**

Nasal epithelial cells RPMI 2650 were used between passage 11 and 25 for all experiments. They were routinely cultured into 25cm² polystyrene cell-culture flasks under standard conditions (humid atmosphere at 37°C and 5% CO2). For cell passaging, cells were washed with PBS at 37°C and then detached with 0.25% (w/v) trypsin-EDTA at 37°C seven days after previous seeding. Cell viability was assessed using a standard trypan blue staining procedure. After counting, cells were seeded in a new flask at a 4 × 10⁴ cells/cm² seeding density. Culture medium was changed every two to three days. Multilayer cell culture was performed into tissue-culture inserts according to the protocol previously described by Reich and Becker [37]. Briefly, 2 × 10⁵ cells/cm² were seeded on permeable
ThinCert® insert membranes and cultured under liquid-covered conditions (LCC) for eight days. After this period, the inserts were lifted at the air-liquid interface (ALI) and cultured for 14 more days to allow the formation of multiple cell layers and tight junctions [37, 38]. Transepithelial electrical resistance (TEER) was measured every two to three days during ALI culture. Experiments were performed in triplicate during at least three independent assays.

**Transepithelial electrical resistance (TEER)**

TEER was measured using a Millicell® ERS-2 Voltohmeter (Merck, Darmstadt, Germany) and the STX01 chopstick electrode according to the manufacturer’s instructions (Fig. 1). Briefly, culture medium or KRB was added to the apical and basolateral compartments of the cell culture to final volumes of 1 ml and 1.5 ml, respectively. Cultures were then left to equilibrate at 37 °C for 30 min before measurements. TEER readings were corrected by subtracting blank filters values and normalized to the surface area of the membrane (1.13 cm²). Cell cultures having TEER values of at least 60 Ω.cm² were used for permeation assays [39].

**MTT cytotoxicity assay**

A MTT cytotoxicity assay was performed to assess artesunate cytotoxicity on epithelial cells RPMI 2650 [40, 41]. Briefly, the cells were seeded at a density of $1.5 \times 10^3$ cells/cm² in 96-well plates. After 24 h, artesunate drug dilutions were added and cells were incubated for 24 h. Following drug exposure, cells were gently washed twice with 100 µl PBS at 37 °C, before adding 110 µl of MTT stock solution diluted in culture medium (final MTT concentration: ~ 0.5 mg/ml). After four hours of incubation, the MTT solution was discarded and 200 µl of DMSO was added to each well. After one hour of incubation, absorbances were read at 485 nm using a Tristar2 LB 942 Multimode Microplate Reader (Berthold Technologies, Germany). Negative (cells without xenobiotics) and positive (cells with 25% v/v DMSO) controls were included. Results were expressed as cell viability (%) relative to negative control (100% viability). According to ISO 10993-5:2009, artesunate dilutions with cell viability percentages above 80% were considered as non-cytotoxic [42, 43]. Experiments were performed in triplicate during three independent assays.

**In vitro permeation studies**

The permeation of the sodium salt of fluorescein (NaF) was used to validate the human nasal mucosa model derived from the culture of nasal epithelial cells RPMI 2650. Before the permeation test, multilayer cultures were rinsed with preheated KRB (37 °C) and their TEER were measured. In another 12-Well plate, 0.5 ml of donor solution was added into the donor chamber and 1.5 ml of KRB (37 °C) in the receptor chamber. The plates were incubated for 1 h under orbital shaking (37 °C, 5% CO₂, humid atmosphere, 100 rpm). Samples (100 µl) were collected from the receptor chamber at fixed time intervals and immediately replaced with fresh KRB (37 °C). Permeated NaF was quantified into each sample using a Tristar2 LB 942 Multimode Microplate Reader (Berthold Technologies, Germany).
Artesunate in vitro deposition study

In vitro deposition of artesunate nasal powder was characterized in an adult male nasal cast (courtesy of Aptar/DTF/Univ. of Tours) with chemical quantification (Fig. 2). The nasal cast model used was designed from Computer Tomography images (CT scan) of a plasticized head model [44] and was previously validated as a predictive model for nasal aerosol deposition [45, 46].

Six unidose (UDSp) devices supplied by Aptar Pharma (Le Vaudreuil, France) were filled with 10 ± 0.5 mg of artesunate powder. One device per nostril was manually actuated into the nasal cast with a fixed insertion depth of 1.5 cm, delivery angle (horizontal plane) of 45° and angle from the centre wall of 4°, after being humidified for 10 min at 3 lpm with a AMGH nebuliser (DTF, Saint-Etienne, France) (Fig. 3). The delivered dose was assessed by weighing each device before and after testing. The different regions of interest (Nose, Olfactory Zone, Turbinates, Nasal Floor, Nasopharynx and Lungs) were rinsed with a PBS solution at pH 8 and frozen at -80°C to ensure artesunate remained stable.

**Analytical methods**

For the permeation study, artesunate quantification was performed with an ultra-high performance liquid chromatography system (AcquityTM, Waters, Massachusetts, USA) coupled to a tandem mass spectrometer (XEVO-TQ-MS, Waters). Chromatographic separation was performed using an Ethylene Bridged Hybrid (BEH) C18 column (1.7 μm, 2.1 × 100 mm, Waters). The mobile phase consisted of 10 mM ammonium formiate in water (pH = 3) and 0.1% (v/v) formic acid in acetonitrile. Calibrators were prepared in KRB at concentrations ranging from 0.5 to 25 000 ng/ml. Before quantification, 20 μL of acetonitrile containing artesunate-d4 internal standard (at a concentration of 2.5 μg/mL) were added to 180 μL of each sample.

For the nasal deposition study, the samples were, firstly, thawed in a water bath at room temperature (20°C). One millilitre (5 × 200 μL) of each sample was deposited on filter membranes mounted on hydrophobic supports (OmniporeTM 10.0 μm, 47 mm). The membranes were thereafter left to dry overnight at room temperature. Artesunate was eluted from the membranes with 5 ml of methanol for each sample and the resulting solutions were analysed for drug determination. Artesunate quantification was performed using an Ultra-High Performance Liquid Chromatography system (Ultimate 3000, Thermo Fischer Scientific, Massachusetts, USA) coupled to a quadrupole-time-of-flight mass spectrometer (Impact II, Bruker, Massachusetts, USA). Chromatographic separation was performed using a Luna Omega Polar C18 column (1.6 μm, 2.1 × 50 mm, Phenomenex, California, USA). The mobile phase consisted of solvent (A), 1 mM ammonium acetate in ultra-pure water and 0.05% (v/v) acetic acid and solvent (B) 1 mM ammonium acetate in methanol and 0.05% (v/v) acetic acid. The lower limit of quantification (LOQ) of artesunate was set at 0.05 μg/g of solution. The drug deposition in each region of the nasal cast was expressed as the fraction (%) of the actual dose (100%) delivered with the device.

**Statistical analysis**

All data management was performed with Microsoft Office Excel and GraphPad Prism 9.2.0 and 9.4.1 software. Statistical analyses, including Kruskal-Wallis test with Dunn’s multiples comparison test and Mann-Whitney test were performed with the significance threshold of α = 0.05. Data are presented as the mean ± standard deviation (SD) of at least two replicates.

**Results**

Cohesion of the human nasal mucosal model for in vitro permeation tests

RPMI 2650 nasal epithelial cells were successively cultured under LCC then ALI conditions for 8 days and 14 days, respectively, to obtain appropriate cultures for in vitro drugs permeation tests. Monitoring of TEER...
values during ALI culture and determination of the $P_{\text{app}}$ of NaF, a low weight hydrophilic marker of paracellular permeation, were used for the validation of the culture model. Average TEER values increased from $23 \pm 4 \Omega \cdot \text{cm}^2$ to $63 \pm 4 \Omega \cdot \text{cm}^2$ from the beginning to the end of ALI culture and demonstrated the gradual formation of tight junctions (Fig. 4). The $P_{\text{app}}$ of NaF was $1.79 \pm 0.07 \times 10^{-6}$ cm/s.

**Effect of artesunate on the viability of nasal epithelial cells**

**RPMI 2650**

MTT assay was performed to determine the effect of artesunate on cultivated nasal cells viability. Cells were incubated with increasing artesunate concentrations for 24h. Cell viability decreased from $86 \pm 10\%$ to $7 \pm 3\%$ upon treatment with artesunate concentrations ranging from 0.75 to 16 µg/ml (Fig. 5). Reduction in cell viability was significant when artesunate concentration was greater than 3 µg/ml (Kruskal-Wallis with Dunn’s multiple comparison, p-value $\leq 0.0049$). The permeation tests using artesunate solution as donor were performed with a donor at a concentration of 0.75 µg/ml as it met the required non-cytotoxicity criterium (cell viability > 80%).

**Artesunate permeation studies**

The permeation profiles of artesunate on the human nasal mucosa model was assessed using a solution (0.75 µg/ml, artesunate stock solution diluted in KRB) or a powder formulation (artesunate powder diluted in corn starch, 20 µg/mg) (Fig. 6). The powder formulation demonstrated
a better permeation efficiency (26.8 ± 6.6%) than the solution formulation (2.1 ± 0.3%) after four hours (p = 0.0003).

The TEER values before and after the permeation tests were not significantly different (Fig. 7). Using solution of artesunate, TEER values were 90 ± 8 Ω.cm², 98 ± 16 Ω.cm² (p = 0.3740), and 88 ± 12 Ω.cm² (p = 0.8791) before, immediately after and 24 h after the tests, respectively. Using artesunate powder, values were 81 ± 10 Ω.cm², 90 ± 15 Ω.cm² (p = 0.2859), and 71 ± 8 Ω.cm² (p = 0.0882).
Pure artesunate powder was filled into 6 UDsp devices and sprayed into each nostril of a human nasal cast model to assess the distribution pattern of the drug. The delivered doses assessed by weighing each device were correct with four devices (9.5 to 10.3 mg), but it exceeded the target dose (10±0.5 mg) with the two last devices (11.6 and 11.9 mg) which were excluded from further analysis. The final amount of artesunate sprayed into each nostril was 9.8±0.4 mg. The two nostrils of the cast were sprayed successively and the total artesunate deposition was measured from the full cast. Interestingly, the olfactory zone received the highest proportion of the sprayed artesunate (44.7±8.6%) as expected, and the respiratory zone of the turbinates received 17.6±3.3% of the dose (Fig. 8). For the other regions of the cast, namely, the nose, the nasal floor, the nasopharynx and, the lungs, the percentages of drug deposition were 13.6±1.3%, 1.1±0.2%, 6.4±0.3% and, 0.11±0.02%, respectively. The total dose recovery of artesunate amounted to 83.5±6.2% of the sprayed dose.

**Discussion**

The objectives of this preclinical proof-of-concept study were to investigate the capacity of artesunate powder to cross the nasal multilayer epithelial cells without local toxicity, and then to reach the olfactory and respiratory zones of the nose after being sprayed in the nostrils.

To that end, an in vitro model of human nasal mucosa was implemented using a two steps culture of nasal epithelial cells, first under liquid-covered conditions (LCC) for eight days in inserts, then at the air-liquid interface (ALI) for 14 more days to allow the formation of multiple cell layers and tight junctions.

This nasal mucosa model was previously proven to mimic the properties of human excised nasal tissue [47]. Indeed, TEER values, which measure tissue integrity and tightness, were demonstrated to be similar to that of the human nasal mucosa ex vivo (75–180 Ω.cm²) [48–51]. Moreover, the distribution of adherent and tight junction proteins, including E-cadherin and zonula occludens-1, as well as the expression of ABC efflux pumps, were shown to be similar to a leaky epithelium [39, 52]. Other studies demonstrated the formation of a mucoid material on the apical surface of the cells during ALI culture [38, 53].

After implementation of the in vitro model of human nasal mucosa, the accuracy of the nasal mucosa model by assessing its barrier function using TEER was confirmed. The TEER values obtained at the end of ALI culture were similar to those previously reported (66 to 79±5 Ω.cm²) [38, 52]. Moreover, the average apparent permeability coefficient of NaF was in agreement with data reported from the same model [37] and from excised human nasal mucosa (3.12×10⁻⁶ ± 1.99×10⁻⁶ cm/s) [49]. Then, the agreement of these results with previous published data allowed us to establish the accuracy of the nasal epithelial cells RPMI 2650 culture.

After validation of the in vitro model of human nasal mucosa, the accuracy of the nasal mucosa model by assessing its barrier function using TEER was confirmed. The TEER values obtained at the end of ALI culture were similar to those previously reported (66 to 79±5 Ω.cm²) [38, 52]. Moreover, the average apparent permeability coefficient of NaF was in agreement with data reported from the same model [37] and from excised human nasal mucosa (3.12×10⁻⁶ ± 1.99×10⁻⁶ cm/s) [49]. Then, the agreement of these results with previous published data allowed us to establish the accuracy of the nasal epithelial cells RPMI 2650 culture.

After validation of this nasal cell model using TTER, artesunate permeation assays were performed with a solution and powder formulation of artesunate. The maximal non-toxic dose of artesunate in solution on nasal epithelial cells RPMI 2650 was assessed using...
a MTT assay after a 24-hour drug exposure. Artesunate was cytotoxic for concentrations greater than 0.75 µg/ml. One possible explanation for AS cytotoxicity was that the RPMI 2650 cell line originates from an anaplastic carcinoma of human nasal septum and that artesunate has an antitumoral activity on several in vitro models of cancer, including oesophageal, and lung cancers [52, 54–56]. Indeed, artesunate is readily hydrolysed in its active metabolite dihydroartemisinin (DHA) under aqueous conditions and the cleavage of DHA’s endoperoxide bridge is believed to induce an oxidative stress responsible for DNA damage, apoptosis, autophagy and ferroptosis [55, 57, 58]. In the light of these results, the permeation tests were performed with a 0.75 µg/ml artesunate solution as average cell
viability for this concentration was above 80%. Moreover, considering artesunate potential cytotoxicity on the cells of the mucosa model, TEER was measured before and after both types of permeation assays to demonstrate that artesunate did not alter the integrity of the model during the permeation tests.

The permeation study showed that the powder formulation had a greater permeation efficiency than the solution (Mann-Whitney test, \( p = 0.0003 \)). This result may be explained by the higher drug concentration on the cell interface for the powder compared to the solution, as previously reported \([38, 59, 60]\). Indeed, the higher drug concentration gradient increases the concentration-dependant passive diffusion of the drug through inter- and intracellular pathways \([59]\). The hydrolysis of artesunate in DHA could have also contributed to the solution lower permeation efficiency by further reducing the concentration gradient of artesunate and its resulting passive diffusion through the cell layers. The greater permeation efficient of the powder formulation using a semi-quantitative biological test was previously demonstrated \([61]\). Beside artesunate anhydrous powder formulation offers a great advantage over the solution because it would prevent the chemical degradation of artesunate and increase the shelf life of the medication.

Considering artesunate in vitro permeation efficiency, it might be possible to optimise the diffusion of the drug by using permeation enhancing excipients such as chitosan \([28]\). Chitosan transiently opens the tight junctions between cells and increases the permeation of drugs through the paracellular pathway \([24, 28]\). Another alternative could be to explore other galenic formulations such as nanostructured lipid carriers (NLCs) \([62]\).

The second objective was to investigate the areas of nasal deposition. The study demonstrated that a very significant amount of sprayed artesunate (45%) reached the olfactory zone allowing a nose-to-brain treatment that could be of major interest for targeting parasites sequestered in the cerebral microvasculature CM. Almost 20% of the sprayed dose reached the respiratory zone, providing also a systemic drug delivery avoiding the hepatic first-pass effect. Those results, combined with the demonstration of the substantial passage of artesunate powder through the nasal mucosa, emphasized the feasibility of an artesunate nasal drug delivery.

**Conclusion**

This proof-of-concept study confirmed the success of intranasal artesunate treatment previously demonstrated during experimental cerebral malaria. Taken together, those results are part of the rationale for the use of intranasal artesunate as a malaria pre-referral treatment. The main advantage of this route compared to intrarectal is the nose-to-brain diffusion of artesunate which could avoid neurovascular impairment due to parasites sequestration. It is worth confirming this hypothesis by preclinical and clinical trials.

**Abbreviations**

ALI: Air-liquid interface; BEH: Ethylene Bridged Hybrid; DHA: Dihydroartemisinin; DMSO: Dimethyl sulfoxide; FBS: Foetal bovine serum; FDA: Food and Drug Administration; KRB: Krebs ring buffer; LCC: Liquid-covered culture; MEM: Minimum essential medium; MS: Mass spectrometry; NaF: Fluorescein sodium salt; NLCs: Nanostructure lipid carriers; NEAA: Non-essential amino-acids; MTI: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS: Phosphate buffer solution; TEER: Transepithelial electrical resistance.

**Acknowledgements**

Authors thanks Pr Eric Truy (Univ Lyon), Dr Emile Dalloneau and Dr Jacchim Confais (Cynbiose), Dr Nathalie Vouoch (Univ Tours) for ENT network, and Dr Damien Salmon & Pr Fabrice Pirot (Univ Lyon). We thank Aptar/DTF/Univ. of Tours for the courtesy and availability of the nasal cast.

**Author contributions**

SP, ALB and YIK conceived and planned the experiments. YIK, AM, EM, NH, GF performed the experiments. YIK, AL, GB, RO and IBS contributed to sample preparation. YIK, SP, ALB, AM, EM, MF and GF contributed to interpretation of the results. YIK, SP, ALB and GF wrote and proofread the manuscript. All authors provided critical feedback and helped shape the research manuscript.

**Funding**

IBS was supported by a grant from Ministry of Religious Affairs (MORA) Scholarship 5000 Doktor and supported by Kediri State Islamic Institute (IAIN) Indonesian Republic. RO was supported by a grant from EDCTP (grant number RIA2017T-2018 WANECAM-2). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Univ Lyon, Malaria Research Unit, SMITH, ICBMS, UMR S246 CNRS-INSA-CPE-University Lyon1, 69622 Villeurbanne, France. 2 Groupement Hospitalier Nord, Institut de Parasitologie et Mycologie Medicale, Hospices Civils de Lyon, 69004 Lyon, France. 3 Laboratory of Biochemistry and Pharmacotoxicology, Lyon-Sud Hospital, Hospices civils de Lyon, 69310 Pierre-Bénite, France. 4 Univ Lyon, CCMS, ICBMS, UMR S246 CNRS-INSA-CPE-University Lyon1, 69622 Villeurbanne, France. 5 Aptar Pharma, Le Vaudreuil, France. 6 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’ORL, d’oto-neurochirurgie et de chirurgie cervico-faciale, 69310 Pierre Bénite, France. 7 Department of Pediatric Otolaryngology—Head & Neck Surgery, Femme Mere Enfant Hospital—Hospices Civils de Lyon, 69008 Lyon, France. 8 Service Pharmacie, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69004 Lyon, France.
References

1. WHO. World malaria report 2021 [Internet]. Geneva: World Health Organization; 2021. [cited 2021 Dec 9]. Available from: https://apps.who.int/iris/handle/10665/350417.

2. Tukwasibwe S, Nakimuli A, Traherne J, Chazara O, Jayaraman J, Trowsdale J, et al. Variations in killer-cell immunoglobulin-like receptor and human leukocyte antigen genes and immunity to malaria. Cell Mol Immunol. 2020;17:799–806.

3. Milner DA. Malaria Pathogenesis. Cold Spring Harb Perspect Med. 2018;10:25669.

4. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokoulo OA, Dondorp AM. Malaria Lancet. 2014;383:23–35.

5. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: biology and disease. 2009;375:557–66.

6. Fanello C, Hoglund RM, Lee SJ, Kayembe D, Ndjowo P, Kabedi C, et al. Rectal Artesunate Landscaping Assessment Report [Internet]. Severe Malaria Observatory. [cited 2021 Oct 11]. Available from: https://www.severemalaria.org/resources/rectal-artesunate-landscaping-assessment-report.

7. Jannin V, Lemagnen G, Gueroult P, Larrouture D, Tuleu C. Rectal route in the 21st Century to treat children. Adv Drug Deliv Rev. 2014;73:34–49.

8. Marijon A, Bonnot G, Fourier A, Bringer C, Lavoignat A, Gagnieu M-C, et al. Efficacy of intranasal artesunate administration of artesunate in experimental cerebral malaria. Malar J. 2014;13:501.

9. Ničič L, Potaš J, Winnicka M, Kralis E, Gružić M, et al. Development, characterisation and nasal deposition of melatonin-loaded pectin/ hyromellose microspheres. Eur Pharm Res. 2020;141:105115.

10. Stoddart P, Satchell SC, Ramnath R. Cerebral microvascular endothelial barrier, astrogliosis, and myelin disruption in optic nerves during fatal cerebral malaria. Am J Pathol. 2002;160:655–66.

11. Abd-Elal RMA, Shamma RN, Rashed HM, Bendas ER. Trans-nasal zolmitriptan nasal powder: a review in acute treatment of migraine. Drugs. 2016;76:1477–84.

12. Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djauplès PG, et al. AVP-825 bypass-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS Study): a comparative randomized clinical trial across multiple attacks. Headache. 2015;55:621–35.

13. Reichl S, Becker K. Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. J Pharm Pharmacol. 2012;64:1621–30.

14. Zeng H-B, Dong L-Q, Xu C, Zhao X-H, Wu L-G. Artesunate promotes brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10:116.

15. Wang Z, Xiong G, Tsang WC, Schätzlein AG, Uchegbu IF. Nose-to-brain delivery. J Pharmocol Exp Ther. 2019;370:593–601.

16. Signorell A, Awor P, Okitawutshu J, Tshefu A, Omoluabi E, Hetzel MW, et al. Health worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate: an operational study in three high burden countries. Infectious Diseases (except HIV/AIDS). 2021. Available from: https://doi.org/10.1111/2040-923X.14415.

17. Selvaraj K, Gowthamanaraj K, Kami VYSR. Nose to brain transport pathways: an overview of potential of nanostructured lipid carriers in nose to brain targeting. Artif Cells Nanomed Biotechnol. 2018;46:2088–95.

18. gratefully acknowledge the financial support from the Department of Chemical Engineering, University of Houston, TX, USA. [cited 2021 Aug 13]. Available from: https://www.elsevier.com/locate/jir.

19. López-García J, Lehocký M, Šáha P. HaCaT keratinocytes as a model for human keratinocytes. J Cell Sci. 2014;127:3569–79.

20. Mercier C, Hodin S, He Z, Perek N, Delavenne X. Pharmacological characterization of the RPMI 2650 model as a relevant tool for assessing the permeability of intranasal drugs. Mol Pharm. 2018;15:2246–56.

21. Di Girolamo MC, Rossini S, Sandri G, Ferrari F, Gavin R, Rassu G, et al. Nanoemulsions for "nose-to-brain" drug delivery. Pharmaceutics. 2019;11:84.

22. Chang Y, Dong J, Izhavong K, Tu J. Comparative numerical modeling of inhaled micron-sized particle deposition in human and rat nasal cavities. Inhal Toxicol. 2015;27:694–705.

23. Bewley S. Getting to the bottom of evidence based medicine. BMJ. 2008;336:764.

24. Monzani A, Orfini L, Mancini C, Cocchi S, Naso S, et al. Artesunate administration for cerebral malaria in adults: nasal administration of artesunate. Acta Anaesthesiol Scand. 2002;46:759–70.

25. Weerasuriya A, Mizisin AP. The blood-nerve barrier: structure and function. Int J Pharm. 2016;515:1–10.

26. Ganger S, Schindowskis K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10:116.

27. Shang Y, Dong J, Izhavong K, Tu J. Comparative numerical modeling of inhaled micron-sized particle deposition in human and rat nasal cavities. Inhal Toxicol. 2015;27:694–705.

28. Selvaraj K, Gowthamanraj K, Kami VYSR. Nose to brain transport pathways: an overview of potential of nanostructured lipid carriers in nose to brain targeting. Artif Cells Nanomed Biotechnol. 2018;46:2088–95.

29. Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44–52.

30. Weerasuriya A, Mizzpin AP. The blood-nerve barrier: structure and functional significance. Methods Mol Biol. 2011;686:149–73.

31. Selvaraj K, Gowthamanraj K, Kami VYSR. Nose to brain transport pathways: an overview of potential of nanostructured lipid carriers in nose to brain targeting. Artif Cells Nanomed Biotechnol. 2018;46:2088–95.
46. Williams G, Cabrera M, Graine L, Le Guelle S, Hauchard N, Jamar F, et al. In vitro and in vivo assessment of regional nasal deposition using scintigraphy from a nasal spray and a nasal powder. Respiratory Drug Deliv. 2021 [cited 2022 Mar 25]; p. 135–40. Available from: https://www.rddonline.com/rdd/article.php? id=1036&ArticleID=2795&Return=1.

47. Gerber W, Steyn D, Kotzé A, Svitina H, Weldon C, Hamman J. Capsaicin and piperine as functional excipients for improved drug delivery across nasal epithelial models. Planta Med. 2019;85:1114–23.

48. Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ. TEER measurement techniques for in vitro barrier model systems. J Lab Autom. 2015;20:107–26.

49. Wengst A, Reichl S. RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. Eur J Pharm Biopharm. 2010;74:290–7.

50. Boucher RC, Yankaskas JR, Cotton CU, Knowles MR, Stutts MJ. Cell culture approaches to the investigation of human airway ion transport. Eur J Respir Dis Suppl. 1987;153:59–67.

51. Cotton CU, Stutts MJ, Knowles MR, Gatzy JT, Boucher RC. Abnormal apical cell membrane in cystic fibrosis respiratory epithelium. An in vitro electrophysiologic analysis. J Clin Invest. 1987;79:80–5.

52. Ladel S, Schlossbauer P, Flamml J, Luksh C, Mizaikoff B, Schindowski K. Improved in vitro model for intranasal mucosal drug delivery: primary olfactory and respiratory epithelial cells compared with the permanent nasal cell line RPMI 2650. Pharmaceutics. 2019;11:367.

53. Kurth L, Veszelka S, Bocsik A, Özsávari B, Puskás LG, Kittel Á, et al. Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. Cytotechnology. 2013;65:395–406.

54. RPMI 2650 | ATCC [Internet]. [cited 2021 Aug 13]. Available from: https:// www.atcc.org/products/ccl-30.

55. Raffetin A, Bruneel F, Roussel C, Thellier M, Buffet P, Caumes Y, et al. Use of artesunate in non-malarial indications. Med Mal Infect. 2018;48:238–49.

56. Picot S. The other face of artesunate: southern drug to treat northern diseases. EBioMedicine. 2015;2:17–8.

57. Haynes RK, Chan H-W, Lung C-M, Ng N-C, Wong H-N, Shek LY, et al. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. ChemMedChem. 2007;2:1448–63.

58. Yao X, Zhao C, Yin H, Wang K, Gao J. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. Acta Pharmacol Sin. 2020;41:1609–20.

59. Asai A, Okuda T, Sonoda E, Yamauchi T, Kato S, Okamoto H. Drug permeation characterization of inhaled dry powder formulations in air-liquid interfaced cell layer using an improved, simple apparatus for dispersion. Pharm Res. 2016;33:487–97.

60. Grainger CJ, Greenwell LL, Martin GP, Forbes B. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm. 2009;71:318–24.

61. Kouakou YI, Omorou R, Said IB, Lavoignat A, Bonnot G, Bienvenu A-L, et al. Assessment of quantitative and semi-quantitative biological test methods of artesunate in vitro. Parasite. 2022;29:18.

62. Agbo CP, Ugwuanyi TC, Ugwuoke WI, McConvile C, Attama AA, Ofokansi KC. Intranasal artesunate-loaded nanostructured lipid carriers: a convenient alternative to parenteral formulations for the treatment of severe and cerebral malaria. J Control Release. 2021;334:224–36.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.